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Abstract Primary diffuse large B-cell lymphoma
(DLBCL) of the central nervous system is an aggressive
malignancy that exhibits unique biological features and
characteristic clinical behaviour, with overall long-term
survival rates of around 20–40 %. Clinical outcome has
improved following the advent of chemoradiation proto-
cols incorporating high-dose methotrexate in the mid-
1980s, but disease relapse and adverse neurocognitive
sequelae remain major clinical challenges. To address
this, investigators have focused on improving drug ther-
apy with novel cytotoxic combinations, monoclonal an-
tibody therapy, and intensive chemotherapy consolida-
tion approaches, in an attempt to improve disease con-
trol whilst reducing the requirement for whole-brain
radiotherapy. Outcomes for patients that are older, im-
munocompromised, or have relapsed/refractory disease
remain unsatisfactory and there is a paucity of clinical
trial data to guide treatment of these groups. This re-
view highlights recent advances in pathobiology, imag-
ing, and clinical management of PCNSL and looks
ahead to research priorities for this rare and challenging
lymphoid malignancy.
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Introduction
Primary central nervous system lymphoma (PCNSL) is a
rare form of non-Hodgkin lymphoma (NHL) comprising
2.2 % of all central nervous system (CNS) tumours [1]. It
encompasses lymphoma exclusively involving the brain,
spinal cord, eyes, meninges, and cranial nerves, with 90–
95 % classified histologically as diffuse large B-cell lym-
phoma (DLBCL). The majority of PCNSL are sporadic and
the incidence increases with age. A minority are attributable
to immunosuppressed states, including HIV infection or
iatrogenic immunosuppression following organ transplanta-
tion. In the era of effective combined antiretroviral therapy
(cART), the frequency of HIV-associated PCNSL has di-
minished [2]. The involvement of critical sites within the
CNS presents both diagnostic and therapeutic challenges,
with outcomes consistently inferior to systemic DLBCL.
Neurocognitive dysfunction and impaired performance sta-
tus are frequent at clinical presentation, whilst histological
confirmation is inherently risky and often yields small
tissue biopsies. Moreover, choice of cytotoxic therapy is
limited by the inability of many drugs employed for sys-
temic NHL treatment to penetrate the blood–brain barrier
(BBB) efficiently. Since the initial description of PCNSL in
1975 [3], treatment algorithms have evolved from whole-
brain radiotherapy (WBRT) as a single-modality treatment
towards a multi-agent, high-dose methotrexate (MTX)-
based, chemotherapy approach where WBRT is reserved
for consolidation or for relapsed disease. Given the rarity
of PCNSL, together with challenges conducting clinical
trials in this patient group, data from randomised studies
are scarce and the level of evidence to guide therapeutic
decisions is often low. This review covers recent advances
in our understanding of biological and clinical aspects of
PCNSL, chiefly primary cerebral DLBCL, and potential
implications for clinical practice.
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Diagnosis
The diagnosis of CNS lymphoma can be a particular challenge
because of lesional response to corticosteroids and MRI fea-
tures that are shared with other pathologies. The majority of
PCNSL are diagnosed via stereotactic biopsy or, less com-
monly, by flow cytometric analysis of cerebrospinal fluid
(CSF) lymphocytes. The conventional approach has been to
avoid surgical resection given the risk of neurological sequel-
ae and lack of therapeutic benefit [4]. However, a recent
unplanned secondary analysis of the G-PCNSL-SG-1 trial
has challenged this view, describing an apparently superior
progression-free survival (PFS) for those undergoing com-
plete or subtotal resection [5]. However, this study had a
number of limitations, and independent verification in a
well-designed and controlled study would be required to
change practice.
Rubenstein et al. recently evaluated the utility of CXCL13
(a mediator of B-cell migration) and IL-10 as diagnostic
biomarkers with the ability to discriminate CNS lymphoma
from other CNS [6•]. The mean concentration of CXCL13
protein in CSF from newly diagnosed PCNSL and SCNSL
was >50-fold higher than in CSF from patients without CNS
lymphoma (p<1×10−7). The concentration of IL-10 in CSF
from PCNSL and SCNSL patients was alsomarkedly elevated
compared with non-lymphoma comparators (p<2.3×10−5).
Notably, for patients with PCNSL, both CXCL13 and IL10
levels below the median were associated with significantly
longer PFS, although statistical independence from pre-
existing clinical risk scores was not shown. The positive
predictive value of CXCL13 and IL-10 elevation in CSF
was 95 % in the identification of newly-diagnosed HIV-
negative PCNSL, with an 88 % negative predictive value
[6•]. These interesting findings potentially offer the opportu-
nity for CNS lymphoma diagnosis without brain biopsy, par-
ticularly where tissue biopsy is deemed high-risk or of low
diagnostic yield. The precision and reproducibility of the
diagnostic cut-offs, however, will need to be prospectively
evaluated.
Magnetic resonance imaging (MRI) is the principal modal-
ity for the detection and monitoring of CNS lesions and recent
publications have focussed on the diagnostic and prognostic
role of advanced MRI techniques. Cellular density is higher
and vascularity is reduced in PCNSL compared to other CNS
malignancies, which is reflected in lower apparent diffusion
coefficient (ADC) and relative cerebral blood flow (rCBV)
values on diffusion-weighted and perfusion MRI, respective-
ly. In support of a prior report suggesting that ADC values are
predictive of outcomes in PCNSL [7], a recent study of 23
patients showed that those with baseline ADCmin <384×
10−6 mm/s had inferior PFS and overall survival (OS) [8]. A
study by the same group reported that low baseline rCBV
predicted inferior OS in a small cohort of 25 patients. Patients
with both low ADCmin and low rCBV had the worst outcomes
with 0 % OS at five years compared to 100 % for those with
high values for both [9]. Amulti-centre phase II study failed to
identify ADC as an independent prognostic factor, but num-
bers were small (n=28) and the two-year PFS was lower in
those with an ADC below the median (57 % vs. 86% p=0.27)
[10•].
Whole-body 18FDG PET-CT has an increased sensitivity
for the detection of systemic DLBCL over conventional CT
staging [11], and has an important role in the exclusion of
systemic lymphoma at presentation. PCNSL lesions charac-
teristically exhibit homogeneous, high-avidity 18FDG uptake
[12], and one small study has suggested that this may assist in
differentiating PCNSL from other intracranial malignancies
where MRI findings are equivocal [13]. Pre-imaging cortico-
steroid therapy is a potential confounding factor, however, and
the additional diagnostic value of 18FDG PET over modern
MRI brain imaging remains poorly defined [12]. The prog-
nostic impact of pre-treatment 18FDG PETwas evaluated in a
retrospective study of 42 patients by Kasenda et al., demon-
strating inferior OS on multivariate analysis (p=0.018) for
patients with increased 18FDG activity relative to cerebellar
uptake at diagnosis [14], consistent with data from an earlier
small (n=17) study [15].
Molecular
Improved characterisation of PCNSL genotype and pheno-
type, albeit from small studies with restricted availability of
diagnostic material, has the potential to provide prognostic
information and identify key molecular pathways that may
serve as potential targets for novel therapeutics [16]. An
activated B-cell like phenotype is typical (95 % MUM-1+,
50–80 % BCL6+, 10 % CD10+), but evidence of ongoing
somatic hypermutation and the preservation of an open read-
ing frame suggests ongoing germinal centre exposure. There-
fore, PCNSL does not neatly conform to either of the principal
molecular profiles identified in systemic DLBCL, namely
germinal centre and activated B-cell subtypes, and appears
to exhibit unique transcriptional features by gene expression
profiling [17]. In contrast to systemic DLBCL, high expres-
sion of BCL-2, BCL-6, and MYC by immunohistochemistry
is frequent (70 % of cases studied [18]) and it has been
speculated that this may contribute to the adverse prognosis
of PCNSL. Recently, the only multi-centre trial to prospec-
tively evaluate PCNSL biomarkers demonstrated that BCL-6
expression, but not MYC, correlated with inferior survival
[19••]. Whilst some studies support this finding [20, 21], other
retrospective analyses found that BCL-6 overexpression cor-
related with superior outcomes [22, 23]. Heterogeneous treat-
ment approaches, sample size, and variable methodologies or
cut-offs may explain these discrepant findings.
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Themost frequent genomic aberration identified in PCNSL
tissue is deletion of 6p21 involving the HLA locus (56–79 %)
[24], a lesion found commonly in DLBCL arising in immune-
privileged sites [25], and represents a potential mechanism for
immune escape. Deletions within the 6q22-23 region (34–
50 %), which contains numerous tumour suppression genes
[20, 24, 26] and homozygous silencing/deletion of the cell
cycle regulator CDKN2A (45–64 %) [24, 27] have apparent
adverse prognostic significance. The MyD-88 L265P activat-
ing mutation appears to be a common molecular aberration
identified (38–50 %), but no impact on clinical outcome has
been demonstrated [21, 24]. The resultant activation of the
NFκB pathway, which is also upregulated by less frequent
mutations or amplification of MALT1 [28], CARD11 [29],
PRDM1 [21, 30], and TBL1XR1 [24], highlights a key sur-
vival pathway and potential therapeutic target. Other dysreg-
ulated signalling pathways of potential significance include B-
cell receptor signalling, with CD79B mutations in 20 % [31,
32], and the JAK/STAT pathway [6•, 33]. Most of the avail-
able data, however, has emerged from relatively small studies,
thus the frequency and prognostic significance of most indi-
vidual genomic aberrations requires further validation, prefer-
ably in the context of prospective clinical trials.
Treatment
Remission Induction
Chemotherapy regimens incorporating HD-MTX are consid-
ered the standard of care as induction therapy for newly-
diagnosed PCNSL, achieving high rates of initial response
when combined with other agents. There is general consensus
that MTX should be administered as a rapid infusion (2–
4 hours) at a dose of at least 3 mg/m2 to maximise therapeutic
CSF concentrations, at an interval of 14–21 days [34]. Higher
absoluteMTX exposure (area under the plasma concentration-
time curve, AUCMTX, >980–1,100 μmol·h/l) correlated with
superior outcomes in two post-hoc and retrospective studies
[35, 36], but these findings have not been reproduced in all
studies [37]. In patients older than 70 years, a retrospective
study found that exceptionally high AUCMTX values
(>2,126 μmol·h/l) inversely correlated with OS on multivar-
iate analysis, without evidence of increased treatment toxicity
[38]. Given significant inter-personal variations in MTX me-
tabolism, an individualised dosing schedule based on pharma-
cokinetic analysis rather than body surface area has been
suggested [39], but not prospectively validated. Recent reports
that polymorphisms in key genes involved in MTX metabo-
lism can influence outcomes and toxicity in adult lymphoma
[40] and paediatric acute lymphoblastic leukaemia [41] war-
rant further investigation in PCNSL.
Modern protocols typically employ between four and eight
cycles of HD-MTX-based therapy but comparative data on
treatment duration is lacking. Historical studies of HD-MTX
response have suggested minimal additional radiological re-
sponse to HD-MTX beyond two cycles [42], but this phenom-
enon is likely to be influenced by a number of factors, includ-
ing partner chemotherapy agents. In the randomised, phase II,
multi-centre IELSG-20 trial, 75 % of maximum responses
were achieved following the first two cycles of treatment.
However, for patients achieving a PR, further tumour response
was observed in patients receiving combination chemotherapy
(HD-MTX/Ara-C, 10/18 patients) but not HD-MTX mono-
therapy [43]. In a recent trial of rituximab, HD-MTX, procar-
bazine and vincristine (R-MPV), CR rates improved from
47 % after five cycles of chemotherapy to 79 % after seven
[10•]. More information on the kinetics of PCNSL response in
the setting of modern immunochemotherapy protocols is re-
quired to inform the optimal duration of induction regimens.
Combination Chemotherapy
To improve on outcomes with single-agent HD-MTX, the
IELSG20 trial assessed the role of combined antimetabolite
therapy, with HD-MTX and cytarabine [43]. This study dem-
onstrated a superior CR rate of 46 % compared to HD-MTX
alone (18 %, p=0.006), with significant improvements in PFS
but not OS (three-year OS 46 % vs. 32 %, p=0.07). Although
a relatively small study (n=79), it remains the first randomised
trial of combination chemotherapy in PCNSL to complete
accrual. Several studies have evaluated the additional value
of BBB-penetrating alkylating agents (such as temozolomide,
procarbazine, and thiotepa), providing non-cross resistant
agents that, unlike antimetabolite chemotherapy, are also cy-
totoxic to cells in G0 of the cell cycle. Rubenstein et al. used
methotrexate, temozolomide, and rituximab (MT-R) induction
followed by etoposide and cytarabine (EA) consolidation in a
prospective multi-centre trial of 44 patients, achieving a two-
year PFS of 57 % and four-year OS of 65 % [19••]. A recent
multi-centre phase II trial reported promising outcomes with
52 patients treated with R-MPVinduction therapy followed by
reduced or standard dose WBRT (23.4Gy (n=31) or 45Gy)
and cytarabine consolidation [10•], achieving median PFS and
OS of 3.3 and 6.6 years, respectively. The addition of thiotepa
to HD-MTX and cytarabine was piloted in a small multi-
centre study (n=20), with inferior results compared to the
IELSG20 trial, attributed to a 50 % protocol reduction in
cytarabine dose (1 g/m2 for four doses) [44], although the
optimal thiotepa dose in this setting has not been ascertained.
The role of thiotepa is currently being evaluated in the ongo-
ing, randomised IELSG32 study (EudraCT number 2009-
012432-32). Although the outcomes of the studies discussed
above appear at least comparable to those from IELSG20,
meaningful comparison across studies is inherently limited
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due to differences in study design, patient characteristics, and
the range of consolidation approaches. Whilst it is clear that
multi-agent chemotherapy is superior to MTX alone, in the
absence of further RCT evidence the optimal combination
remains uncertain.
Rituximab
In contrast to the survival advantage witnessed in systemic
DLBCL, the benefit of combining rituximab with chemother-
apy for PCNSL remains unclear. Rituximab has limited CNS
penetration with intravenous administration, achieving 0.1–
4.4 % of plasma concentrations [45]. Single-agent efficacy
was demonstrated in 12 patients with refractory/relapsed
PCNSL with radiographic response to intravenous rituximab
monotherapy in 36 % [46] and encouraging response rates
have been achieved with rituximab 375–500 mg/m2 in con-
junction with combination chemotherapy in single-arm trials
[8, 10•, 19••, 45, 47]. Two recent studies have retrospectively
compared immunochemotherapy outcomes against historical
chemotherapy regimens to extrapolate the relative benefit of
rituximab. Although the quality of responses appears to be
improved with the addition of rituximab, no survival advan-
tage has yet been demonstrated on multivariate analysis [48,
49]. Results from ongoing randomised studies (IELSG32:
NCT01011920, and HOVON 105 PCNSL/ALLG NHL24
trial: EudraCT 2009-014722-42) are essential to define the
role of rituximab in induction therapy for PCNSL.
Intrathecal Therapy
Detectable meningeal disease is present in 15 % at diagnosis
[50] and may serve as a reservoir for PCNSL cells. The
presence of meningeal disease does not appear to have a
prognostic impact, irrespective of whether intrathecal therapy
is employed [50–52]. The additional benefit of intrathecal
therapy remains unclear given the ability of HD-MTX to
achieve therapeutic concentrations within the CSF [53]. Two
recent non-randomised studies have suggested higher rates of
early relapse with omission of intrathecal therapy in compar-
isonwith otherwise identical polychemotherapy regimens [54,
55]. Several other studies, however, have failed to demon-
strate a clear improvement in response rates or OS with
intrathecal therapy, leading to omission of intrathecal treat-
ment from many current chemotherapy regimens [51, 56]. In
light of the limited ability of immunotherapy to cross the
BBB, however, the role of CSF-directed therapy needs to be
re-evaluated. Notably, a phase I study of intraventricular
rituximab/methotrexate in 14 patients with isolated CNS lym-
phoma relapse, including six PCNSL patients, reported ORR
and CR rates of 75 % and 43 %, respectively [57•].
Consolidation Treatment
WBRT
Following introduction of HD-MTX-based chemotherapy,
WBRT (36-45Gy) has continued to be employed to consoli-
date responses and provide more durable disease control.
Delayed neurotoxicity [58, 59•], however, is a major limita-
tion that is clinically evident in approximately one-third of
patients, particularly with increasing age, and associated with
significant morbidity and mortality. The only phase III trial
thus far to complete accrual in PCNSL aimed to demonstrate
that omission of consolidation WBRT after MTX-based che-
motherapy resulted in non-inferior OS rates. Although out-
comes suggested that WBRTcan be safely omitted in selected
patients achieving CR with induction chemotherapy, this am-
bitious study failed to meet its primary endpoint and major
limitations in study design, amendments, and protocol adher-
ence limit interpretation of these data [58]. A recent systematic
review, which assessed outcomes of chemotherapy versus
combinedmodality treatment using a decision-analytic model,
has suggested improvements in both survival and quality-
adjusted life years with consolidation WBRT for those
<60 years only [60]. The emerging outcome data for HDT-
ASCT consolidation for younger, sufficiently fit patients (de-
scribed below), however, challenges this approach. Deferring
WBRT in patients achieving CR with chemotherapy is a
particularly attractive concept for those >60 years.
In an attempt to ameliorate the long-term neurocognitive
sequelae of WBRT at standard doses, investigators have
assessed the value of reduced dose WBRT (rdWBRT). Inferi-
or outcomes have been described with a reduced consolidation
WBRT dose (30.6Gy) following CHOD/BVAM induction
therapy in a non-randomised comparison [61]. Morris et al.
recently reported encouraging rates of disease control using
23.4Gy radiotherapy as consolidation therapy following the
R-MPV protocol, with a PFS of 7.7 years for the selected
subgroup (n=31) achieving CR with immunochemotherapy.
Prospective neuropsychological evaluation demonstrated no
overall cognitive decline, in 12 patients assessed 48 months
after rdWBRT [10•]. The PFS for the whole cohort (n=52),
however, was 3.3 years in this single-arm study. Importantly, a
randomised study of R-MPV versus R-MPV-rdWBRT is
planned (RTOG 1114).
Chemotherapy Consolidation
The efficacy of high-dose chemotherapy and autologous stem
cell transplantation (HDT-ASCT) was first demonstrated in
the context of relapsed/refractory PCNSL [62] and has been
subsequently studied as a consolidation approach in first-line
therapy [63] in younger, fit patients. The concept of eradicat-
ing minimal residual disease by the use of myeloablative
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doses of non-cross resistant agents that efficiently penetrate
the BBB is supported by non-comparative phase II clinical
trial outcomes. Thiotepa is a small, lipophilic polyfunctional
alkylator that efficiently penetrates the BBB and has been
incorporated as a key agent in HDT-ASCT protocols for
PCNSL. Schorb et al. retrospectively analysed outcomes from
the largest reported cohort (n=105) treated with thiotepa/
BCNU HDT-ASCT first-line consolidation following HD-
MTX-based induction. The median age was 54 and median
KPS was 80 %. HDT-ASCT-related mortality was 2.8 %, and
36 % of patients received additional WBRT. Outcomes were
encouraging, with a five-year OS of 79% and amedian PFS and
OS of 85 and 121 months, respectively [64•]. On an intention-
to-treat basis, long-term follow-up data was recently reported for
some of these patients included in two prospective single-arm
phase II trials involving HD-MTX and HD-Ara-C/thiotepa in-
duction followed by carmustine/thiotepa-conditioned ASCT,
with (n=30) or without (n=13) WBRT. A total of 34 of 43
patients proceeded to ASCT and median OS for the whole
cohort was 104 months with a five-year OS of 70 % [65]. In
most studies, evidence of chemosensitivity to agents employed
in induction or salvage regimens is not an absolute prerequisite
to proceed to HDT-ASCT. Long-term remissions have been
demonstrated in patients who failed to achieve PR with HD-
MTX-based induction prior to HDT-ASCT, although outcomes
in this group as a whole are inferior [64•, 66]. No direct com-
parison of conditioning regimens in PCNSL has been conduct-
ed, however, earlier results usingBEAM (carmustine, etoposide,
cytarabine, melphalan) have been disappointing, with a PFS of
9.3 months in one study (n=14) [67].
Other groups have investigated dose-intensive, non-
myeloablative, consolidation chemotherapy as an alternative
strategy. A multi-centre prospective trial of MT-R induction
followed by EA consolidation resulted in a median PFS of
28 months and four-year OS of 65 % [19••]. Notwithstanding
a relatively high rate of early disease progression, disease
control using this chemotherapy consolidation strategy ap-
pears at least comparable with chemoradiation protocols. The-
se results need further validation in an independent cohort.
This strategy is potentially attractive in older or unfit patients,
who are ineligible for HDT-ASCT and have higher rates of
neurotoxicity with WBRT. Data from a phase II study, pre-
sented in abstract form, demonstrated the feasibility of HD-
Ara-C (3 g/m2/d for two days) as a consolidation approach for
patients with a median age of 72 years [68]. Response-adapted
consolidation based on the results of interim response assess-
ment is another potential approach; a small retrospective study
(n=40) did not identify a difference in outcome with omission
of WBRT or ASCT in those achieving early CR at interim
assessment (n=10) [69], but requires prospective validation.
Efficacy and toxicity data from a number of ongoing
randomised trials in Europe and the US comparing thiotepa-
based HDT-ASCT with WBRT (IELSG32: NCT01011920),
or non-myeloablative chemotherapy (CALGB 51101:
NCT01511562), should help inform the optimal consolidation
strategy in PCNSL.
Salvage
Currently, there exists no standard treatment approach for
patients with relapsed and refractory PCNSL. Published data
are largely restricted to small, uncontrolled, retrospective
studies, in which outcomes are influenced by a number of
parameters including prior therapies and response durations.
With these caveats in mind, the overall response rates reported
from both prospective and retrospective studies are typically
10–40 %. A recent retrospective analysis of MTX re-
challenge described high response rates amongst 39 patients
re-treated at a median of 26 months from initial diagnosis with
MTX-based therapy [70]. For patients with early relapse or
refractory disease, a salvage regimen employing non-cross-
resistant chemotherapy regimens is rational. Mappa et al.
recently reported a retrospective study (n=22) of salvage
therapy with rituximab, ifosfamide, and etoposide for refrac-
tory (n=11) or relapsed PCNSL; in this high-risk patient
group the ORR was 41 % with a two-year OS of 25 % [71].
In studies where eligible patients have proceeded to HDT-
ASCT, available data support the use of thiotepa-based HDT-
ASCT in relapsed PCNSL, resulting in five-year EFS and OS
rates of 37.8% and 51.4%, respectively, in the largest study to
date (n=79) [66]. Results of WBRTas a salvage treatment are
equivalent to those reported with many salvage chemotherapy
regimens, with a PFS of 10–10.8 months, but are rarely
durable [72, 73]. WBRT is most often employed as consoli-
dation following salvage chemotherapy or as a palliative
single-modality treatment.
Temozolomide has been evaluated in a number of retro-
spective [74–76] and prospective [77, 78] studies, with and
without rituximab, demonstrating modest efficacy and some
durable responses (ORR 14–53%, one-year OS 31–71%) but
disappointing PFS of <2-2.8 months. Use of pemetrexed as an
alternative antifolate agent has been reported in two small
cohorts of heavily pre-treated patients with a median PFS of
5.7–5.8 months and one-year OS of 45 % [79, 80] and studies
addressing its efficacy are ongoing. Other agents showing
limited single-agent efficacy in heavily pre-treated patients
include bendamustine [81] and topotecan [82]. There is inter-
est in assessing the efficacy of other drugs, such as
l e na l i d om id e (NCT01956695 ) , poma l i dom id e
(NCT01722305), temsirolimus (NCT00942747), ibrutinib,
and other agents targeting B-cell signalling [16]. Given that
a significant proportion of patients will not be fit for or not
respond to salvage chemotherapy, there is an urgent need for
the assessment of novel agents or treatment combinations in
the context of clinical trials.
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Older Patients
With the median age at diagnosis of PCNSL rising above
63 years [83, 84] and over 20 % patients older than 80 years
[85], establishing optimal treatment in older patients is of
paramount importance. The true incidence may be
underestimated if there is reluctance to biopsy cerebral lesions
in this age group, as the possible treatment options are con-
sidered to be limited. Symptoms can bemisinterpreted in older
patients resulting in significant treatment delays [86]. Altered
metabolism of cytotoxic drugs [38] and impaired organ func-
tion [83] present additional therapeutic challenges.
Age is consistently reported as a principle adverse prog-
nostic factor in PCNSL. Defining the ‘older patient’ is prob-
lematic, however, as physiological fitness does not always
equate to chronological age and published studies have ap-
plied different age thresholds. In practical terms, this cohort is
often defined by the ability to tolerate therapies such asWBRT
(<60 years) or HDT-ASCT (<70-75 years). The G-PCNSL-
SG-1 trial reported a median OS of 12.5 months in those older
than 70 years (versus 26.6 months for younger patients), with
a marked difference in PFS for those in CR after induction
therapy (16.1 vs. 35 months p=0.024) not explained by
WBRT-related neurotoxicity alone [87]. The use of WBRT
results in high rates of clinically significant neurotoxicity in
patients over 60 years [88]. Consequently, WBRT is often
avoided in those achieving CR with induction chemotherapy.
WBRT offers only modest efficacy as sole therapy, with a
median OS of 5–12 months [89], but may offer a palliative
approach for some patients. Population-based studies, howev-
er, suggest a reluctance to use HD-MTX protocols in older
patients, with 36–39 % receiving WBRT alone [85, 89]. In a
cohort of 22 patients aged 80–90 years, HD-MTX was well-
tolerated, with only two patients requiring dose reductions and
a two-year OS of 33 % [86]. By contrast, a population-based
study (n=40) reported that 25 % of patients >60 years were
unable to tolerate more than one cycle of MTX-based chemo-
therapy due to renal, haematological, or pulmonary toxicity,
with an additional two treatment-related deaths (5 %) [89].
A number of studies have focused on the efficacy of
chemotherapy withoutWBRT in older patients. A randomised
phase II study, published in abstract form, randomised 98
patients (median age 72 years, median KPS 70 %) to primary
treatment with either MT (MTX-temozolomide) or MPV-A
(methotrexate, procarbazine, vincristine, cytarabine). Efficacy
endpoints favoured MPV-A (median OS 31 versus 14 months
p=0.2) with no increase in toxicity [68], although the study
lacked the power to demonstrate statistical superiority. A
phase II trial of chemoimmunotherapy with MTX, lomustine,
procarbazine, and rituximab in 28 patients reported a median
OS of 17.5 months [47], similar to the median OS of
15 months reported in a preceding trial without rituximab
[90]. Omission of lomustine from the regimen has resulted
in improved tolerability (G. Illerhaus, Stuttgart, personal com-
munication, 2014) and formal reporting of the outcome is
awaited.
PCNSL in People Living With HIV
Immunodeficiency-associated PCNSL is a distinct clinical
entity characterised by Epstein Barr virus (EBV)-positivity
and the presence of multifocal, often necrotic lesions on
gadolinium-enhanced MRI. Incidence inversely correlates
with CD4 counts and, historically, survival was strongly in-
fluenced by HIV-related comorbidities. In the cART era, the
frequency of HIV-associated PCNSL has fallen whilst surviv-
al has improved [91], although outcomes remain inferior to
those of immunocompetent patients [92]. Surrogate measures
are often used for diagnosis, using a combination of thallium-
201 SPECT scanning and presence of EBV in the CSF [93,
94], therefore availability of diagnostic material for biologic
studies is limited. With increasing use of intensive treatment
regimens, however, histological diagnosis will have a greater
influence on choice of treatment and should be obtained
where feasible.
Given that HIV seropositivity is typically an exclusion
criterion for prospective PCNSL studies, therapy has been
empirically adopted from treatment of PCNSL in immuno-
competent patients, akin to the paradigm of systemic lympho-
ma therapy [95]. Case reports of isolated responses to cART
alone are few [96] and subject to selection bias, therefore, it is
not recommended as the sole treatment modality. Use of either
WBRT or chemotherapy independently reduced the risk of
death in a large retrospective HIV-PCNSL cohort [91]. HD-
MTX-based regimens have been tolerated in immunodeficient
patients, but trials in the cART era are lacking [97] and data is
particularly scarce on patients receiving combination chemo-
therapy [92, 98]. There is an isolated case report of successful
ASCT [99]. Despite this, in large population-based studies,
reasonable survival rates of 54% at one year [100] and 22.8%
at five years [101] were reported.
Post-Treatment Evaluation and Monitoring
Treatment-related neurotoxicity occurring months to years
following completion of therapy is frequently a progressive
condition that can be disabling, even fatal, in some patients.
The risk of neurotoxicity correlates with the dose of WBRT
and increasing age [102, 103]. Whether combination chemo-
therapy confers additive risk of neurotoxicity is not yet clear,
largely due to the paucity of prospective psychometric assess-
ment in many trials. A standardised battery of neuropsycho-
logical and quality of life assessments have been published
and are being incorporated into ongoing prospective studies
[103]. Recently, Doolittle et al. [59•] reported on the long-term
cognitive outcomes in 80 PCNSL survivors who achieved CR
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with HD-MTX-based protocols, of which 19 % incorporated
WBRTat a dose of 45Gy or greater. At a median follow-up of
5.5 years, 47 % of patients treated with chemoradiation pro-
tocols demonstrated impairment in multiple cognitive do-
mains, compared to 9–16 % receiving chemotherapy alone
(p=0.0237). Correa et al. presented cognitive assessment on
50 patients, 24 of whom received WBRT plus chemotherapy
and 26 who received chemotherapy alone. Quality of life was
lower in WBRT patients, with significant reductions through-
out all cognitive domains compared to age-matched controls
[104]. Interpretation of both cross-sectional studies, however,
is limited by lack of formal assessment of pre- and post-
treatment cognitive status. Almost all patients with delayed
neurotoxicity have marked white matter changes on MRI
[102], and the extent of white matter changes has been shown
to be correlated inversely with cognitive function in some
studies [59•] but not others [104]. This is a common post-
treatment finding in PCNSL, however, and is not an adequate
surrogate for formal psychometric assessment.
A large, single-centre retrospective (n=209) of PCNSL
patients monitored with post-treatment brain imaging every
4–6 months demonstrated that, of 124 patients in CR, 80 % of
relapses that occurred were symptomatic and detected be-
tween surveillance scans [105•]. Given the incidence of late
relapses and lack of evidence for early salvage treatment, there
is no clear indication for surveillance imaging outside of
clinical trials.
Relatively few studies have reported survival rates beyond
five years, with varying incidence of late relapse and limited
evidence for emergence of a survival plateau. Relapses can
occur more than 10 years after initial diagnosis, with evidence
of clonal persistence [106]. In a single-centre retrospective
cohort, of those achieving CR with induction therapy (n=
268), 10 out of 48 patients in ongoing remission at five years
subsequently relapsed (20.8 %) [106]. Prospective follow-up
of 41 patients treated with chemoradiotherapy at a median of
12 years has suggested the emergence of a survival plateau
with a 10-year OS of 24 % [107]. Long-term follow-up of
patients in two trials involving ASCT consolidation (n=43)
reported that 50 % of relapses (6/12) occurred more than five
years post-treatment [65] and emphasises the need for long-
term follow-up in PCNSL survivors to fully evaluate treat-
ment efficacy.
Conclusions
Information from randomised clinical trials is essential to
further improve the management of PCNSL and answer crit-
ical questions such as the optimal induction chemotherapy and
consolidation strategy. Correlative biological studies in the
context of prospective trials will refine our knowledge of
PCNSL biology and potentially enable identification of those
with poor-risk disease at diagnosis, for whom intensification
of treatment and/or novel therapeutics may be of benefit.
Focussing on neurocognitive outcomes and long-term
follow-up of survivors will allow refinement of the balance
between treatment toxicity and cure.
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